These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 18786258

  • 1. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab Study Group.
    Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
    [Abstract] [Full Text] [Related]

  • 2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 3. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008 Dec; 9(3):197-202. PubMed ID: 18457473
    [Abstract] [Full Text] [Related]

  • 4. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
    Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A.
    Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
    [Abstract] [Full Text] [Related]

  • 5. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 7. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 26; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 8. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 9. Belimumab: a guide to its use in systemic lupus erythematosus.
    Scott LJ, Burness CB, McCormack PL.
    BioDrugs; 2012 Jun 01; 26(3):195-9. PubMed ID: 22428610
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 01; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 11. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW, BLISS-52 Study Group, BLISS-76 Study Group.
    Arthritis Rheum; 2012 Jul 01; 64(7):2328-37. PubMed ID: 22275291
    [Abstract] [Full Text] [Related]

  • 12. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr 01; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 13. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G, Cervera R.
    Drugs Today (Barc); 2010 Dec 01; 46(12):891-9. PubMed ID: 21589946
    [Abstract] [Full Text] [Related]

  • 14. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
    Wiglesworth AK, Ennis KM, Kockler DR.
    Ann Pharmacother; 2010 Dec 01; 44(12):1955-61. PubMed ID: 21081710
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.
    Ann Rheum Dis; 2016 Feb 01; 75(2):323-31. PubMed ID: 26338095
    [Abstract] [Full Text] [Related]

  • 16. Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus.
    Prete M, Leone P, Frassanito MA, Desantis V, Marasco C, Cicco S, Dammacco F, Vacca A, Racanelli V.
    Lupus; 2018 Oct 01; 27(12):1926-1935. PubMed ID: 30180771
    [Abstract] [Full Text] [Related]

  • 17. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.
    Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P.
    J Drug Assess; 2013 Oct 01; 2(1):40-8. PubMed ID: 27536436
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
    Witcher J, Fleischmann R, Chindalore VL, Hansen RJ, Hu L, Radtke D, Voelker J, Gomez E, McColm J.
    Br J Clin Pharmacol; 2016 May 01; 81(5):908-17. PubMed ID: 26648084
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
    Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.
    Ann Rheum Dis; 2016 Feb 01; 75(2):332-40. PubMed ID: 26293163
    [Abstract] [Full Text] [Related]

  • 20. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D.
    Arthritis Res Ther; 2020 May 04; 22(1):102. PubMed ID: 32366280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.